Increased dietary folic acid intake may lead to adverse health effects, including inflammation and neurotoxicity, ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Of 44 children with both autism and folate receptor alpha autoantibodies, two thirds treated with the drug showed language ...

According to the National Institutes of Health, about seven in 10 autistic children have folate receptor autoantibodies, a ...

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers ...

Role of Folate Receptor Alpha Testing Mirvetuximab soravtansine, an antibody-drug conjugate targeting FRα, represents the newest approved therapy in ovarian cancer. Testing considerations include ...

For example, when we inactivate (knock out) the folate receptor (Forl1) gene-its protein product which is a receptor molecule that brings vitamin B9 (folic acid) into cells is eliminated, and the ...

in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. The U.S. Food and Drug Administration granted full approval to Elahere in ...

Mirvetuximab soravtansine shows no significant HRQoL detriments despite TEOEs in FRα+ platinum-resistant ovarian cancer patients. The phase 3 MIRASOL trial confirms improved progression-free and ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant ...